Dr. Xingli Wang joined Fosun Pharma Group in January 2023, and is currently the Executive President of Fosun Pharma, Co-Chief Executive Officer (Co-CEO) of Innovative Medicines Division and Chief Executive Officer (CEO) of Global R&D center of Fosun Pharma.
Before joining Fosun Pharma Group, Dr. Wang held various leadership and management positions with increasing responsibilities in Schering-Plough, Merck and Novartis and has extensive experience in global drug R&D, including leading large-scale global clinical trials and successfully submitting multiple IND/NDA applications.
Dr. Wang was tenured Professor at Baylor College of Medicine and awarded the Distinguished Scientist Award by the American Heart Association, Chang Jiang Scholar of Shandong University and the national distinguished professorship.
Dr. Wang is also a registered medical practitioner in Australia.
His academic research fields include clinical cardiovascular disease, population genetics, molecular cell biology, etc., and he has more than 220 publications in SCI journals (including Nature Medicine, JCI, Circulation, Circulation Research, PNAS, Diabetes, ATVB and JBC, etc.).